Clinical Trial Update: Clinical Evaluation of Florbetapir F 18 (18F-AV-45) [Phase 2]

View source ↗

Summary

Phase 2 clinical evaluation of Florbetapir F-18 (18F-AV-45) completed; results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease
• Cognitive Impairment

Drugs mentioned

• Florbetapir F-18 (18F-AV-45) (Florbetapir F-18)

Snippet

Sponsor: Avid Radiopharmaceuticals | Conditions: Alzheimer Disease, Mild Cognitive Impairment | Phase 2 | Status: COMPLETED | Results posted: 2018-06-14